Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXSM NYSE:BHC NASDAQ:JAZZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$244.31$230.88$96.09▼$260.19$12.57B0.61.18 million shs853,789 shsBHCBausch Health Cos$4.93+0.5%$5.24$4.57▼$8.69$1.83B0.422.89 million shs3.27 million shsJAZZJazz Pharmaceuticals$243.47$228.38$105.00▼$243.81$15.29B0.32845,721 shs766,842 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics0.00%+0.89%+5.54%+44.98%+135.12%BHCBausch Health Cos0.00%+2.93%-6.10%-8.20%-30.73%JAZZJazz Pharmaceuticals0.00%+5.85%+1.42%+30.23%+121.50%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$244.31$230.88$96.09▼$260.19$12.57B0.61.18 million shs853,789 shsBHCBausch Health Cos$4.93+0.5%$5.24$4.57▼$8.69$1.83B0.422.89 million shs3.27 million shsJAZZJazz Pharmaceuticals$243.47$228.38$105.00▼$243.81$15.29B0.32845,721 shs766,842 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics0.00%+0.89%+5.54%+44.98%+135.12%BHCBausch Health Cos0.00%+2.93%-6.10%-8.20%-30.73%JAZZJazz Pharmaceuticals0.00%+5.85%+1.42%+30.23%+121.50%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXSMAxsome Therapeutics 2.95Moderate Buy$258.955.99% UpsideBHCBausch Health Cos 1.80Reduce$8.0062.44% UpsideJAZZJazz Pharmaceuticals 2.84Moderate Buy$246.061.06% UpsideCurrent Analyst Ratings BreakdownLatest AXSM, JAZZ, and BHC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026JAZZJazz Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)6/17/2026AXSMAxsome Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$275.00 ➝ $300.006/15/2026AXSMAxsome Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/12/2026JAZZJazz Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)6/11/2026AXSMAxsome Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$380.006/11/2026AXSMAxsome Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeReduce ➝ Overweight6/10/2026JAZZJazz Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$281.00 ➝ $307.006/9/2026JAZZJazz Pharmaceuticals Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform6/9/2026JAZZJazz Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$256.006/4/2026AXSMAxsome Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/27/2026JAZZJazz Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$234.00 ➝ $253.00(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXSMAxsome Therapeutics$708.24M17.75N/AN/A$1.75 per share139.61BHCBausch Health Cos$10.53B0.17$7.35 per share0.67$1.02 per share4.83JAZZJazz Pharmaceuticals$4.27B3.58$16.26 per share14.97$71.07 per share3.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXSMAxsome Therapeutics-$183.17M-$3.73N/A52.31N/A-26.59%-267.16%-28.53%8/3/2026 (Estimated)BHCBausch Health Cos$157M-$3.24N/A1.35N/A-11.47%-2,922.77%5.63%7/29/2026 (Estimated)JAZZJazz Pharmaceuticals-$356.15M-$0.02N/A10.890.210.66%14.56%5.25%8/4/2026 (Estimated)Latest AXSM, JAZZ, and BHC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2026Q2 2026BHCBausch Health Cos$0.96N/AN/AN/A$2.56 billionN/A5/5/2026Q1 2026JAZZJazz Pharmaceuticals$4.67$6.34+$1.67$4.43$978.66 million$974.98 million5/4/2026Q1 2026AXSMAxsome Therapeutics-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million4/29/2026Q1 2026BHCBausch Health Cos$0.81$0.78-$0.03-$3.76$2.37 billion$2.46 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ABHCBausch Health CosN/AN/AN/AN/AN/AJAZZJazz PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXSMAxsome Therapeutics2.271.391.32BHCBausch Health Cos54.681.320.97JAZZJazz Pharmaceuticals0.952.041.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXSMAxsome Therapeutics81.49%BHCBausch Health Cos78.65%JAZZJazz Pharmaceuticals89.14%Insider OwnershipCompanyInsider OwnershipAXSMAxsome Therapeutics20.60%BHCBausch Health Cos20.67%JAZZJazz Pharmaceuticals4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXSMAxsome Therapeutics38051.46 million40.86 millionOptionableBHCBausch Health Cos20,300374.02 million296.71 millionOptionableJAZZJazz Pharmaceuticals2,89062.82 million60.24 millionOptionableAXSM, JAZZ, and BHC HeadlinesRecent News About These CompaniesSimplify Asset Management Inc. Sells 19,448 Shares of Jazz Pharmaceuticals PLC $JAZZJuly 4 at 5:51 AM | marketbeat.comBoston Trust Walden Corp Buys 94,750 Shares of Jazz Pharmaceuticals PLC $JAZZJuly 3 at 3:27 AM | marketbeat.comJazz Pharmaceuticals (JAZZ) Price Forecast: Will Breakout Confirm Higher Highs?July 2 at 5:03 PM | fxempire.comFPictet Asset Management Holding SA Has $31.78 Million Holdings in Jazz Pharmaceuticals PLC $JAZZJuly 1, 2026 | marketbeat.comJazz Pharmaceuticals (JAZZ) is a Top-Ranked Momentum Stock: Should You Buy?June 30, 2026 | zacks.comLouisiana State Employees Retirement System Invests $3.33 Million in Jazz Pharmaceuticals PLC $JAZZJune 28, 2026 | marketbeat.comJazz Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade)June 26, 2026 | seekingalpha.comAssenagon Asset Management S.A. Makes New Investment in Jazz Pharmaceuticals PLC $JAZZJune 26, 2026 | marketbeat.comJazz Pharmaceuticals (JAZZ) Stock Gets Fair Value Boost As Ziihera Views Split AnalystsJune 25, 2026 | finance.yahoo.comSG Americas Securities LLC Grows Stock Position in Jazz Pharmaceuticals PLC $JAZZJune 24, 2026 | marketbeat.comFaithward Advisors LLC Buys 9,065 Shares of Jazz Pharmaceuticals PLC $JAZZJune 24, 2026 | marketbeat.comRockefeller Capital Management L.P. Decreases Stake in Jazz Pharmaceuticals PLC $JAZZJune 21, 2026 | marketbeat.comJazz and AbCellera sign deal for T-cell engagers in solid tumoursJune 19, 2026 | finance.yahoo.comJazz Pharmaceuticals PLC $JAZZ Shares Acquired by Pacer Advisors Inc.June 19, 2026 | marketbeat.comJAZZ & ABCL Team Up to Develop Next-Generation Solid Tumor TherapiesJune 18, 2026 | zacks.comJazz Pharmaceuticals plc: Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific AntibodiesJune 18, 2026 | finanznachrichten.deJazz Pharma and AbCellera announces preclinical research collaborationJune 18, 2026 | pharmabiz.comPInsider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells 1,157 Shares of StockJune 18, 2026 | insidertrades.comPerceptive Advisors LLC Buys Shares of 170,000 Jazz Pharmaceuticals PLC $JAZZJune 18, 2026 | marketbeat.comClough Capital Partners L P Acquires Shares of 12,517 Jazz Pharmaceuticals PLC $JAZZJune 18, 2026 | marketbeat.comArdsley Advisory Partners LP Invests $8.50 Million in Jazz Pharmaceuticals PLC $JAZZJune 18, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAXSM, JAZZ, and BHC Company DescriptionsAxsome Therapeutics NASDAQ:AXSM$244.31 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$241.50 -2.81 (-1.15%) As of 07/2/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Bausch Health Cos NYSE:BHC$4.92 +0.03 (+0.51%) Closing price 07/2/2026 03:59 PM EasternExtended Trading$4.86 -0.07 (-1.34%) As of 07/2/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Jazz Pharmaceuticals NASDAQ:JAZZ$243.47 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$247.31 +3.84 (+1.58%) As of 07/2/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
